Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Nyxoah S.A.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NYXOAH ANNOUNCES FIRST U.S. COMMERCIAL PATIENTS IMPLANTED WITH GENIO SYSTEM EARLY COMMERCIAL LAUNCH DEMONSTRATES STRONG PHYSICIAN DEMAND, SUCCESSFUL PRE-AUTHORIZATIONS, AND WIDESPREAD PAYOR COVERAGE MONT-SAINT-GUIBERT, BELGIUM  OCTOBER 6, 2025 7:00 CET / 1:00 ET  NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH), A MEDICAL TECHNOLOGY COMPANY THAT DEVELOPS BREAKTHROUGH TREATMENT ALTERNATIVES FOR OBSTRUCTIVE SLEEP APNEA (OSA), TODAY ANNOUNCED THAT THE FIRST U.S. COMMERCIAL PATIENTS HAVE BEEN SUCCESSFULLY IMPLANTED WITH THE GENIO SYSTEM FOLLOWING FDA APPROVAL. "WE ARE THRILLED TO ANNOUNCE THAT THE FIRST COMMERCIAL PATIENTS HAVE NOW RECEIVED GENIO IMPLANTS, MARKING A SIGNIFICANT MILESTONE IN BRINGING THIS INNOVATIVE THERAPY TO OSA PATIENTS IN THE U.S.," SAID OLIVIER TAELMAN, CHIEF EXECUTIVE OFFICER.

NYXOAH ANNOUNCES FIRST U.S. COMMERCIAL PATIENTS IMPLANTED WITH GENIO SYSTEM

REGULATED INFORMATION PUBLICATION RELATING TO TRANSPARENCY NOTIFICATIONS MONT-SAINT-GUIBERT (BELGIUM), OCTOBER 3, 2025 , 10:30 PM CET / 4:30 PM ET  IN ACCORDANCE WITH ARTICLE14 OF THE ACT OF 2 MAY 2007 ON THE DISCLOSURE OF LARGE SHAREHOLDINGS, NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH) ANNOUNCES THAT IT RECEIVED A TRANSPARENCY NOTIFICATION AS DETAILED BELOW. VESTAL POINT CAPITAL ON OCTOBER 1, 2025, NYXOAH RECEIVED A TRANSPARENCY NOTIFICATION FROM VESTAL POINT CAPITAL FOLLOWING AN ACQUISITION OR DISPOSAL OF VOTING SECURITIES OR VOTING RIGHTS.

PUBLICATION RELATING TO TRANSPARENCY NOTIFICATIONS

NYXOAH PROVIDES AN UPDATE ON EXPANDED MIDDLE EAST PRESENCE NEW CENTERS IN DUBAI, KUWAIT, AND ABU DHABI FOLLOWING FIRST GENIO IMPLANT IN THE REGION EARLIER IN 2025 MONT-SAINT-GUIBERT, BELGIUM  SEPTEMBER 23, 2025, 10:10PM CET / 4:10PM ET  NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH), A MEDICAL TECHNOLOGY COMPANY THAT DEVELOPS BREAKTHROUGH TREATMENT ALTERNATIVES FOR OBSTRUCTIVE SLEEP APNEA (OSA), TODAY ANNOUNCED THE CONTINUED EXPANSION OF ITS COMMERCIAL FOOTPRINT IN THE MIDDLE EAST, FOLLOWING THE FIRST SUCCESSFUL GENIO IMPLANT IN ABU DHABI IN SEPTEMBER 2025. THE MIDDLE EAST IS HOME TO WORLD-CLASS HEALTHCARE SYSTEMS, RENOWNED KEY OPINION LEADERS, AND CENTERS OF EXCELLENCE WITH OUTSTANDING FACILITIES.

NYXOAH PROVIDES AN UPDATE ON EXPANDED MIDDLE EAST PRESENCE

REGULATED INFORMATION PUBLICATION RELATING TO TRANSPARENCY NOTIFICATIONS MONT-SAINT-GUIBERT (BELGIUM), SEPTEMBER 5, 2025 , 10:30 PM CET / 4:30 PM ET  IN ACCORDANCE WITH ARTICLE14 OF THE ACT OF 2 MAY 2007 ON THE DISCLOSURE OF LARGE SHAREHOLDINGS, NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH) ANNOUNCES THAT IT RECEIVED A TRANSPARENCY NOTIFICATION AS DETAILED BELOW. ON SEPTEMBER 4, 2025, NYXOAH RECEIVED A TRANSPARENCY NOTIFICATION FROM COCHLEAR LIMITED AND COCHLEAR INVESTMENTS PTY LTD FOLLOWING A PASSIVE CROSSING OF A THRESHOLD.

NYXOAH ANNOUNCES UPCOMING INVESTOR EVENTS MONT-SAINT-GUIBERT, BELGIUM  SEPTEMBER 2, 2025, 10:30PM CET / 4:30PM ET  NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH)(NYXOAH OR THE COMPANY), A MEDICAL TECHNOLOGY COMPANY THAT DEVELOPS BREAKTHROUGH TREATMENT ALTERNATIVES FOR OBSTRUCTIVE SLEEP APNEA (OSA), TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN THE FOLLOWING EVENTS DURING SEPTEMBER: 2025 WELLS FARGO HEALTHCARE CONFERENCE SEPTEMBER 3RD  BOSTON, MA CANTOR GLOBAL HEALTHCARE CONFERENCE 2025 SEPTEMBER 4TH  NEW YORK, NYFIRESIDE CHAT: 11:30-12:00 PM ETWEBCAST: CANTOR FIRESIDE CHAT WEBCAST MORGAN STANLEY 23 RD ANNUAL GLOBAL HEALTHCARE CONFERENCE SEPTEMBER 9TH  NEW YORK, NY PRESENTATION TIME: 5:35-6:10 PM ETWEBCAST: : MORGAN STANLEY FIRESIDE CHAT WEBCAST BAIRD'S 2025 GLOBAL HEALTHCARE CONFERENCE SEPTEMBER 10TH  NEW YORK, NY A LIVE WEBCAST OF THE EVENTS CAN BE ACCESSED BY VISITING NYXOAH'S INVESTOR RELATIONS WEBSITE AND WILL BE AVAILABLE FOR REPLAY FOLLOWING THE EVENTS. THE COMPANY WILL ALSO BE AVAILABLE FOR 1X1 MEETINGS WITH INSTITUTIONAL INVESTORS ATTENDING THE EVENTS.

NYXOAH ANNOUNCES UPCOMING INVESTOR EVENTS

REGULATED INFORMATION NYXOAH REPORTS SECOND QUARTER FINANCIAL AND OPERATING RESULTS FDA APPROVES GENIO SYSTEM FOR U.S. MARKET; COMPANY BEGINS COMMERCIAL LAUNCH MONT-SAINT-GUIBERT, BELGIUM  AUGUST 18, 2025, 10:10PM CET / 4:10 PM ET  NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH) (NYXOAH OR THE COMPANY), A MEDICAL TECHNOLOGY COMPANY THAT DEVELOPS BREAKTHROUGH TREATMENT ALTERNATIVES FOR OBSTRUCTIVE SLEEP APNEA (OSA) THROUGH NEUROMODULATION, TODAY REPORTED FINANCIAL AND OPERATING RESULTS FOR THE SECOND QUARTER OF 2025. RECENT FINANCIAL AND OPERATING HIGHLIGHTS RECEIVED U.S. FOOD AND DRUG ADMINISTRATION (FDA) PRE-MARKET APPROVAL (PMA) FOR THE GENIO SYSTEM, THE FIRST AND ONLY BILATERAL HYPOGLOSSAL NEUROSTIMULATION THERAPY APPROVED IN THE U.S. KICKED OFF THE U.S. COMMERCIAL LAUNCH OF THE GENIO SYSTEM DREAM PIVOTAL STUDY DATA PUBLISHED IN THE JOURNAL OF CLINICAL SLEEP MEDICINE REVENUE FOR THE SECOND QUARTER OF 2025 WAS 1.3 MILLION, COMPARED TO 0.8 MILLION IN THE SECOND QUARTER OF 2024, REPRESENTING 74% YEAR OVER YEAR GROWTH CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS WERE 43.0 MILLION AT JUNE 30, 2025, COMPARED TO 63.0 MILLION AT THE END OF MARCH 31, 2025.

NYXOAH REPORTS SECOND QUARTER FINANCIAL AND OPERATING RESULTS

NYXOAH ANNOUNCES PRELIMINARY RESULTS FOR THE SECOND QUARTER OF 2025 MONT-SAINT-GUIBERT, BELGIUM  AUGUST 11, 2025, 7:00AM CET / 1:00AM ET  NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH)(NYXOAH OR THE COMPANY), A MEDICAL TECHNOLOGY COMPANY THAT DEVELOPS BREAKTHROUGH TREATMENT ALTERNATIVES FOR OBSTRUCTIVE SLEEP APNEA (OSA), TODAY ANNOUNCED CERTAIN PRELIMINARY, UNAUDITED FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2025 AND OTHER BUSINESS UPDATES. PRELIMINARY, UNAUDITED SECOND QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATES ANNOUNCED ON AUGUST 8, 2025, THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED THE GENIO SYSTEM FOR A SUBSET OF ADULT PATIENTS WITH MODERATE TO SEVERE OSA WITH AN APNEA-HYPOPNEA INDEX (AHI) OF GREATER THAN OR EQUAL TO 15 AND LESS THAN OR EQUAL TO 65.

NYXOAH ANNOUNCES PRELIMINARY RESULTS FOR THE SECOND QUARTER OF 2025

INSIDE INFORMATION REGULATED INFORMATION NYXOAH RECEIVES APPROVAL FROM FDA FOR GENIO SYSTEM FOR THE TREATMENT OF OBSTRUCTIVE SLEEP APNEA U.S. COMMERCIALIZATION OFFICIALLY LAUNCHED MONT-SAINT-GUIBERT, BELGIUM  AUGUST 8, 2025, 10:10PM CET / 4:10PM ET  NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH) (NYXOAH OR THE COMPANY), A MEDICAL TECHNOLOGY COMPANY THAT DEVELOPS BREAKTHROUGH TREATMENT ALTERNATIVES FOR OBSTRUCTIVE SLEEP APNEA (OSA) THROUGH NEUROMODULATION, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED THE GENIO SYSTEM FOR A SUBSET OF PATIENTS WITH MODERATE TO SEVERE OSA WITH AN APNEA-HYPOPNEA INDEX (AHI) OF GREATER THAN OR EQUAL TO 15 AND LESS THAN OR EQUAL TO 65. GENIO IS A DIFFERENT APPROACH TO HYPOGLOSSAL NERVE STIMULATION (HGNS) FOR THE TREATMENT OF OSA.

NYXOAH RECEIVES APPROVAL FROM FDA FOR GENIO SYSTEM FOR THE TREATMENT OF OBSTRUCTIVE SLEEP APNEA

NYXOAH TO RELEASE SECOND QUARTER 2025 FINANCIAL RESULTS ON AUGUST 18, 2025

NYXOAH'S DREAM PIVOTAL STUDY DATA PUBLISHED IN THE JOURNAL OF CLINICAL SLEEP MEDICINE MONT-SAINT-GUIBERT, BELGIUM  JULY 28, 2025, 10:05PM CET / 4:05PM ET  NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH)(NYXOAH OR THE COMPANY), A MEDICAL TECHNOLOGY COMPANY THAT DEVELOPS BREAKTHROUGH TREATMENT ALTERNATIVES FOR OBSTRUCTIVE SLEEP APNEA (OSA), TODAY ANNOUNCED THAT DATA FROM ITS DREAM PIVOTAL STUDY WAS PUBLISHED ONLINE IN THE JOURNAL OF CLINICAL SLEEP MEDICINE. THE DREAM PIVOTAL STUDYPRESENTS COMPREHENSIVE 12-MONTH SAFETY AND EFFICACY RESULTS THAT SUPPORTED THE COMPANY'S PMA SUBMISSION TO THE FDA.

Nyxoah S.A.

NYXH

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Nyxoah S.A.

NYXH.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

NYXH